by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
VANCOUVER, Washington, Sept. 12, 2016 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has entered into...
by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
BURLINGTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has made two key appointments to its leadership team: Carolyn Beaty Scimemi, Esq., an experienced compliance and legal professional, as Chief...
by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
MADISON, Wis., Sept. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple...
by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
Conclusions Drawn from Results of Celsion’s HEAT Study Prompted NIH Analysis; Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit Compared to Treatment with RFA Alone Abstract Accepted for Oral Presentation at the 2016...
by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
SAN DIEGO and TORONTO, Sept. 12, 2016 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that it has...
